Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial

被引:40
|
作者
Op den Kamp, Yvo J. M. [1 ]
de Ligt, Marlies [1 ]
Dautzenberg, Bas [1 ]
Kornips, Esther [1 ]
Esterline, Russell [2 ]
Hesselink, Matthijs K. C. [1 ]
Hoeks, Joris [1 ]
Schrauwen-Hinderling, Vera B. [1 ,3 ]
Havekes, Bas [4 ]
Oscarsson, Jan [5 ]
Phielix, Esther [1 ]
Schrauwen, Patrick [1 ]
机构
[1] Maastricht Univ, NUTRIM Sch Nutr & Translat Res Metab, Dept Nutr & Movement Sci, Med Ctr, Maastricht, Netherlands
[2] AstraZeneca, BioPharmaceut R&D, Gaithersburg, MD USA
[3] Maastricht Univ, Radiol & Nucl Med, Med Ctr, Maastricht, Netherlands
[4] Maastricht Univ, Internal Med, Med Ctr, Maastricht, Netherlands
[5] AstraZeneca, BioPharmaceut R&D, Late Stage Dev Cardiovasc Renal & Metab, Gothenburg, Sweden
关键词
INSULIN SENSITIVITY; RESPIRATION CHAMBER; SECRETION; MEN;
D O I
10.2337/dc20-2887
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE SGTL2 inhibitors increase urinary glucose excretion and have beneficial effects on cardiovascular and renal outcomes. The underlying mechanism may involve caloric restriction-like metabolic effects due to urinary glucose loss. We investigated the effects of dapagliflozin on 24-h energy metabolism and insulin sensitivity in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS There were 26 patients with type 2 diabetes randomized to a 5-week double-blind, crossover study with a 6- to 8-week washout. Indirect calorimetry was used to measure 24-h energy metabolism and the respiratory exchange ratio (RER), both by whole-room calorimetry and by ventilated hood during a two-step euglycemic-hyperinsulinemic clamp. Results are presented as the differences in least squares mean (95% CI) between treatments. RESULTS Evaluable patients (n = 24) had a mean (SD) age of 64.2 (4.6) years, BMI of 28.1 (2.4) kg/m(2), and HbA(1c) of 6.9% (0.7) (51.7 [6.8] mmol/mol). Rate of glucose disappearance was unaffected by dapagliflozin, whereas fasting endogenous glucose production (EGP) increased by dapagliflozin (+2.27 [1.39, 3.14] mu mol/kg/min, P < 0.0001). Insulin-induced suppression of EGP (-1.71 [-2.75, -0.63] mu mol/kg/min, P = 0.0036) and plasma free fatty acids (-21.93% [-39.31, -4.54], P = 0.016) was greater with dapagliflozin. Twenty-four-hour energy expenditure (-0.11 [-0.24, 0.03] MJ/day) remained unaffected by dapagliflozin, but dapagliflozin reduced the RER during daytime and nighttime, resulting in an increased day-to-nighttime difference in the RER (-0.010 [-0.017, -0.002], P = 0.016). Dapagliflozin treatment resulted in a negative 24-h energy and fat balance (-20.51 [-27.90, -13.12] g/day). CONCLUSIONS Dapagliflozin treatment for 5 weeks resulted in major adjustments of metabolism mimicking caloric restriction, increased fat oxidation, improved hepatic and adipose insulin sensitivity, and improved 24-h energy metabolism.
引用
收藏
页码:1334 / 1343
页数:10
相关论文
共 50 条
  • [1] Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial (vol 44, pg 1334, 2021)
    den Kamp, Yvo J. M. Op
    de Ligt, Marlies
    Dautzenberg, Bas
    Kornips, Esther
    Esterline, Russell
    Hesselink, Matthijs K. C.
    Hoeks, Joris
    Schrauwen-Hinderling, Vera B.
    Havekes, Bas
    Oscarsson, Jan
    Phielix, Esther
    Schrauwen, Patrick
    DIABETES CARE, 2022, 45 (05) : 1297 - 1297
  • [2] Effects of 5 weeks of treatment with dapagliflozin, a SGLT2 inhibitor, on energy metabolism in patients with type 2 diabetes
    Op den Kamp, Y.
    de Ligt, M.
    Dautzenberg, B. D.
    Esterline, R.
    Hoeks, J.
    Schrauwen-Hinderling, V. B.
    Havekes, B.
    Oscarsson, J.
    Phielix, E.
    Schrauwen, P.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S115 - S115
  • [3] Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non -diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial
    Cherney, David Z., I
    Dekkers, Claire C. J.
    Barbour, Sean J.
    Cattran, Daniel
    Gafor, Abdul Halim Abdul
    Greasley, Peter J.
    Laverman, Gozewijn D.
    Lim, Soo Kun
    Di Tanna, Gian Luca
    Reich, Heather N.
    Vervloet, Marc G.
    Wong, Muh Geot
    Gansevoort, Ron T.
    Heerspink, Hiddo J. L.
    LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (07): : 582 - 593
  • [4] Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism
    op den Kamp, Yvo J. M.
    Gemmink, Anne
    de Ligt, Marlies
    Dautzenberg, Bas
    Kornips, Esther
    Jorgensen, Johanna A.
    Schaart, Gert
    Esterline, Russell
    Pava, Diego A.
    Hoeks, Joris
    Schrauwen-Hinderling, Vera B.
    Kersten, Sander
    Havekes, Bas
    Koves, Timothy R.
    Muoio, Deborah M.
    Hesselink, Matthijs K. C.
    Oscarsson, Jan
    Phielix, Esther
    Schrauwen, Patrick
    MOLECULAR METABOLISM, 2022, 66
  • [5] Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study
    Henry, Robert R.
    Rosenstock, Julio
    Edelman, Steven
    Mudaliar, Sunder
    Chalamandaris, Alexandros-Georgios
    Kasichayanula, Sreeneeranj
    Bogle, Allyson
    Iqbal, Nayyar
    List, James
    Griffen, Steven C.
    DIABETES CARE, 2015, 38 (03) : 412 - 419
  • [6] Effects of the SGLT2 Inhibitor Dapagliflozin on Epicardial and Visceral Fat in Patients With Type 2 Diabetes and Metabolic Syndrome: a Randomized Controlled Trial
    Shiina, Kazuki
    Hirano, Masaharu
    Miwa, Takashi
    Ito, Rokuro
    Sikuma, Junpei
    Odawara, Masato
    Chikamori, Taishiro
    CIRCULATION, 2017, 136
  • [7] DAPAGLIFLOZIN, AN SGLT2 INHIBITOR FOR THE TREATMENT OF TYPE 2 DIABETES
    Demaris, K. M.
    White, J. R.
    DRUGS OF TODAY, 2013, 49 (05) : 289 - 301
  • [8] Dapagliflozin, an SGLT2 inhibitor, for diabetes
    Hanefeld, Markolf
    Forst, Thomas
    LANCET, 2010, 375 (9733): : 2196 - 2198
  • [9] Safety and efficacy of the SGLT2 inhibitor dapagliflozin in older patients with type 2 diabetes
    Fioretto, P.
    de Bruin, T. W.
    Johnsson, E.
    Ptaszynska, A.
    Parikh, S.
    List, J. F.
    DIABETOLOGIA, 2013, 56 : S383 - S383
  • [10] Effect of SGLT2 inhibitor dapagliflozin on skeletal muscle fatty acid metabolism in patients with type 2 diabetes
    Gemmink, A.
    op den Kamp, Y. J. M.
    de Ligt, M.
    Dautzenberg, B.
    Esterline, R.
    Hoeks, J.
    Schrauwen-Hinderling, V. B.
    Kersten, S.
    Havekes, B.
    Koves, T. R.
    Muio, D. M.
    Hesselink, M. K. C.
    Oscarsson, J.
    Phielix, E.
    Schrauwen, P.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S5 - S5